$Role of nutritional supplementation in heart failure with reduced ejection fraction$
Código QR

Código QR

Role of nutritional supplementation in heart failure with reduced ejection fraction

Guardado en:

Detalles Bibliográficos
Autores principales:	Yash Paul Sharma, Pulkit Chhabra, Prashant Panda, Ajay Shunmugarajan
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Surgery RD1-811 Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/a14a6daa6f654a0ba022b5e065b12ab1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Distal axillary vein puncture to eliminate risk of pneumothorax - A study
por: Pulkit Chhabra, et al.
Publicado: (2021)

Determinants of gait speed in patients with heart failure with reduced ejection fraction
por: Aylin Tanrıverdi, et al.
Publicado: (2021)

A profile of heart failure with preserved ejection fraction in a teaching institute
por: Gaurav Aggarwal, et al.
Publicado: (2021)

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: M Rizzo, et al.
Publicado: (2020)

Classification of heart failure: A farewell to ejection fraction?
por: Thomas F. Lüscher
Publicado: (2021)

The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
por: Pankaj Jariwala, et al.
Publicado: (2021)

Machine learning based diagnosis of heart failure with preserved ejection fraction among South Asian patients
por: Ananya Achanta, et al.
Publicado: (2021)

Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
por: Neal M Dixit, et al.
Publicado: (2021)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Mauro Gori, et al.
Publicado: (2021)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Veronika Zach, et al.
Publicado: (2020)

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction
por: Ali Çoner, et al.
Publicado: (2021)

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Giuseppe MC Rosano, et al.
Publicado: (2019)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Davide Stolfo, et al.
Publicado: (2019)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Hidekatsu Fukuta
Publicado: (2020)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Davide Margonato, et al.
Publicado: (2020)

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
por: M Rizzo, et al.
Publicado: (2020)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
por: Pankaj Jariwala, et al.
Publicado: (2021)

Echocardiographic assessment of inter and intraventricular dyssynchrony in heart failure patients with reduced ejection fraction and normal QRS duration using tissue doppler imaging, 2D echocardiography and M-mode
por: Varun Mitra Vallabhapurapu, et al.
Publicado: (2021)

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Sebastian Rosch, et al.
Publicado: (2020)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Sebastiaan HC Klaassen, et al.
Publicado: (2020)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Wan Ting Tay, et al.
Publicado: (2021)

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
por: Nicholas K Brownell, et al.
Publicado: (2021)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Mackram F Eleid, et al.
Publicado: (2021)

Evaluation of potential underuse of cardiac resynchronization therapy for heart failure with reduced ejection fraction
por: Makoto Takano, et al.
Publicado: (2021)

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
por: Osama A. Amin, et al.
Publicado: (2021)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: James L Januzzi, et al.
Publicado: (2021)

Cardiogenic shock complicating acute myocardial infarction in COVID pandemic – Clinical characteristics, management and outcomes
por: Yash Paul Sharma, et al.
Publicado: (2021)

Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction
por: Nancy Luo, MD, MHS, et al.
Publicado: (2021)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021)

Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure
por: Li-fang Ye, et al.
Publicado: (2021)

Vagal Neuromodulation in Chronic Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
por: Lucas Bonacossa Sant'Anna, et al.
Publicado: (2021)

Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
por: Berkay Ekici, et al.
Publicado: (2021)

Link Between Synovial and Myocardial Inflammation: Conceptual Framework to Explain the Pathogenesis of Heart Failure with Preserved Ejection Fraction in Patients with Systemic Rheumatic Diseases
por: Milton Packer
Publicado: (2020)

Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
por: Yibo He, et al.
Publicado: (2021)

Role of NT-pro BNP in predicting mortality in heart failure
por: Kamal Kant Jena, et al.
Publicado: (2021)

Accuracy of global longitudinal and territorial longitudinal strain in determining myocardial viability in comparison to single-photon emission computed tomography in out of window period anterior wall myocardial infarction patients
por: Yash Paul Sharma, et al.
Publicado: (2021)

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
por: Ali Çoner
Publicado: (2021)

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
por: Mustafa Doğduş, et al.
Publicado: (2021)

Deep Learning Predicts Heart Failure With Preserved, Mid-Range, and Reduced Left Ventricular Ejection Fraction From Patient Clinical Profiles
por: Mohanad Alkhodari, et al.
Publicado: (2021)

Role of Levosimendan in acute decompensated heart failure
por: V.K. Katyal, et al.
Publicado: (2021)